Stem Cells Advances in Ophthalmology: A Review

Article Sidebar

PDF
Published: Jun 20, 2022
DOI: https://doi.org/10.47191/ijmscrs/v2-i6-13
Keywords:
.

Main Article Content

Cesar Alberto Ortiz Orozco
Hospital Civil de Guadalajara Dr Juan I Menchaca, Departamento de cirugía, Guadalajara, Jalisco, Mexico
Samari Maciel Armenta
Department of anesthesiology, Faculty of Medicine, University of Guadalajara. Guadalajara, Jalisco, México.
Felix Osuna Gutiérrez
School of Medicine, Autonomous University of Guadalajara, Guadalajara, Jalisco, Mexico
José María Zepeda Torres
School of Medicine, Autonomous University of Guadalajara, Guadalajara, Jalisco, Mexico

Abstract

Vision is one of the most valuable senses humans have. However, there are quite a few clinical conditions that threaten and compromise its function. Advances in the development of therapeutic strategies have led us to use stem cells to treat from chronic-degenerative pathologies to infectious-contagious diseases. Taking this into account, it is of vital importance to evaluate the possibility of future therapeutic strategies using stem cells to treat and manage ophthalmic pathologies.

Article Details

How to Cite
Cesar Alberto Ortiz Orozco, Samari Maciel Armenta, Felix Osuna Gutiérrez, & José María Zepeda Torres. (2022). Stem Cells Advances in Ophthalmology: A Review. International Journal of Medical Science and Clinical Research Studies, 2(6), 516–520. https://doi.org/10.47191/ijmscrs/v2-i6-13
Issue
Vol. 2 No. 6 (2022): Volume 02 Issue 06 June 2022
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Park J, Lee OE. Association between vision impairment and suicidal ideation among older adults: Results from National Survey on Drug Use and Health. Disability and Health Journal. 2020;100939:100939.

II. Health USD, Services H. NIH Stem Cell Information Home Page. In Bethesda, MD: National Institutes of Health; 2016.

III. Mani C, Reddy PH, Palle K. DNA repair fidelity in stem cell maintenance, health, and disease. Biochim Biophys Acta Mol Basis Dis. 2020;1866(4):165444.

IV. Özmert E, Arslan U. Management of retinitis pigmentosa by Wharton’s jelly derived mesenchymal stem cells: preliminary clinical results. Stem Cell Res Ther. 2020;11(1):25.

V. Liu Y, Chen SJ, Li SY, Qu LH, Meng XH, Wang Y, et al. Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients. Stem Cell Research & Therapy. 2017;8(1):1186 13287–017–0661–8.

VI. Foltz LP, Clegg DO. Patient-derived induced pluripotent stem cells for modelling genetic retinal dystrophies. Prog Retin Eye Res. 2019;68:54–66.

VII. Millán-Rivero JE, Nadal-Nicolás FM, García-Bernal D, Sobrado-Calvo P, Blanquer M, Moraleda JM, et al. Human Wharton’s jelly mesenchymal stem cells protect axotomized rat retinal ganglion cells via secretion of anti-inflammatory and neurotrophic factors. Sci Rep. 2018;8(1):16299.

VIII. Aladdad AM, Kador KE. Adult Stem Cells, Tools for Repairing the Retina. Current Ophthalmology Reports. 2019;1007 40135–019–00195–.

IX. Weiss JN, Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow derived stem cells in the treatment of Usher syndrome. Stem Cell Investig. 2019;6:31.

X. Sanjurjo-Soriano C, Erkilic N, Baux D, Mamaeva D, Hamel CP, Meunier I, et al. Genome editing in patient iPSCs corrects the most prevalent USH2A mutations and reveals intriguing mutant mRNA expression profiles. Mol Ther Methods Clin Dev. 2020;17:156–73.

XI. McLenachan S, Wong EYM, Zhang X, Leith F, Moon SY, Zhang D, et al. Generation of two induced pluripotent stem cell lines from a patient with compound heterozygous mutations in the USH2A gene. Stem Cell Research. 2019;36:101420.

XII. Kuriyan AE, Albini TA, Townsend JH, Rodriguez M, Pandya HK, Leonard RE, et al. Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD. New England Journal of Medicine. 2017;376(11):1047–1053.

XIII. Fields M, Cai H, Gong J, Del Priore L. Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD. Cells. 2016;5(4):44.

XIV. Cheng SK, Park EY, Pehar A, Rooney AC, Gallicano GI. Current progress of human trials using stem cell therapy as a treatment for diabetes mellitus. Am J Stem Cells. 2016;5(3):74–86.

XV. Da Cruz L, Fynes K, Georgiadis O, Kerby J, Luo YH, Ahmado A, et al. Phase 1 clinical study of an embryonic stem cell–derived retinal pigment epithelium patch in age-related macular degeneration. Nature Biotechnology. 2018;36(4):328–337.

XVI. Albert S, Garanto A, Sangermano R, Khan M, Bax NM, Hoyng CB, et al. Identification and Rescue of Splice Defects Caused by Two Neighboring Deep-Intronic ABCA4 Mutations Underlying Stargardt Disease. The American Journal of Human Genetics. 2018;102(4):517–527.

XVII. Hu J, Kady N, Macabasco A, Gorin MB, Matynia A, Radu RA. Complement Dysregulation is Evidenced in iPSC-derived RPE Cells from Stargardt Disease patients. Invest Ophthalmol Vis Sci. 2020;61(7):1507–1507.

XVIII. Parfitt DA, Lane A, Ramsden CM, Carr A-JF, Munro PM, Jovanovic K, et al. Identification and correction of mechanisms underlying inherited blindness in human iPSC-derived optic cups. Cell Stem Cell. 2016;18(6):769–81.

XIX. Gain P, Jullienne R, He Z, Aldossary M, Acquart S, Cognasse F, et al. Global survey of corneal transplantation and eye banking. JAMA Ophthalmol. 2016;134(2):167–73.

XX. Price FW Jr, Whitson WE, Collins KS, Marks RG. Five-year corneal graft survival. A large, single-center patient cohort. Arch Ophthalmol. 1993;111(6):799–805.

XXI. The collaborative corneal transplantation studies (CCTS): Effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol. 1992;110(10):1392.

XXII. Dana MR, Qian Y, Hamrah P. Twenty-five-year panorama of corneal immunology: emerging concepts in the immunopathogenesis of microbial keratitis, peripheral ulcerative keratitis, and corneal transplant rejection. Cornea. 2000;19(5):625–43.

XXIII. Omoto M, Katikireddy KR, Rezazadeh A, Dohlman TH, Chauhan SK. Mesenchymal stem cells home to inflamed ocular surface and suppress allosensitization in corneal transplantation. Invest Ophthalmol Vis Sci. 2014;55(10):6631.

XXIV. Oh JY, Lee RH, Yu JM, Ko JH, Lee HJ, Ko AY, et al. Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response. Mol Ther. 2012;20(11):2143–52.

XXV. Jia Z, Jiao C, Zhao S, Li X, Ren X, Zhang L, et al. Immunomodulatory effects of mesenchymal stem cells in a rat corneal allograft rejection model. Exp Eye Res. 2012;102:44–9.

XXVI. Treacy O, O’Flynn L, Ryan AE, Morcos M, Lohan P, Schu S, et al. Mesenchymal stem cell therapy promotes corneal allograft survival in rats by local and systemic immunomodulation: MSCs prolong corneal allograft survival. Am J Transplant. 2014;14(9):2023–36.

XXVII. Sasamoto Y, Sasamoto N, Tran J, Mishra A, Ksander BR, Frank MH, et al. Investigation of factors associated with ABCB5-positive limbal stem cell isolation yields from human donors. Ocul Surf. 2020;18(1):114–20.

XXVIII. Puri S, Sun M, Mutoji KN, Gesteira TF, Coulson-Thomas VJ. Epithelial cell migration and proliferation patterns during initial wound closure in normal mice and an experimental model of limbal stem cell deficiency. Invest Ophthalmol Vis Sci. 2020;61(10):27.

XXIX. Baradaran-Rafii A, Asl NS, Ebrahimi M, Jabbehdari S, Bamdad S, Roshandel D, et al. The role of amniotic membrane extract eye drop (AMEED) in in vivo cultivation of limbal stem cells. Ocul Surf. 2018;16(1):146–53.

XXX. Zhang W, Wang Y, Kong J, Dong M, Duan H, Chen S. Therapeutic efficacy of neural stem cells originating from umbilical cord-derived mesenchymal stem cells in diabetic retinopathy. Scientific Reports. 2017;7(1):1038 41598–017–00298–2.

XXXI. Arden GB, Sivaprasad S. The pathogenesis of early retinal changes of diabetic retinopathy. Documenta Ophthalmologica. 2012;124(1):15–26

Most read articles by the same author(s)